Mesenkia Therapeutics is a Swedish-Japanese biotechnology company built on over three decades of collaborative research. Their modular KITAIbodies® is designed to develop first-in-class biologics for aggressive cancers with a high unmet medical need.
Their lead program targets glioblastoma, while our KITAIbodies® are designed to enable future therapeutics across multiple indications and modalities. Through strategic collaborations with pharmaceutical companies, they aim to accelerate drug development and create value for patients worldwide.
The company’s mission is to bring first-in-class therapies targeting HVEM-driven cancers into the clinic by combining scientific excellence, platform innovation and strategic partnerships.
